Palantir a high-risk investment with ’a one-of-a-kind growth and margin model’
ROCKVILLE/LONDON - MaxCyte, Inc. (NASDAQ:MXCT; LSE:MXCT) and Ori Biotech Ltd. announced Wednesday a strategic collaboration to improve efficiency and productivity in cell therapy manufacturing by integrating their respective platforms.
The partnership combines MaxCyte’s ExPERT platform and Flow Electroporation technology with Ori’s IRO manufacturing platform to optimize yield and streamline manufacturing timelines of engineered T cells. The companies will initially evaluate CD19 CAR expression via CRISPR knock-in in activated T cells as their test system.
MaxCyte’s technology provides transfection capabilities at clinical scale, while Ori’s platform offers automated fluid handling, customizable mixing, and tubeless sterile connections. Together, these complementary technologies aim to help therapy developers produce clinically relevant quantities of gene-edited T cells more efficiently.
"We are excited to collaborate with the team at Ori Biotech, combining our respective strengths and innovative technologies to significantly enhance manufacturing processes," said Maher Masoud, President and CEO of MaxCyte.
Jason C. Foster, CEO of Ori Biotech, added that the partnership demonstrates Ori’s commitment to providing "flexible and scalable solutions that address critical challenges in cell and gene therapy manufacturing."
The collaboration seeks to enable developers of advanced therapies to adopt integrated solutions that accelerate the path from research to commercialization of cell therapies.
According to the press release statement, MaxCyte’s technology is currently utilized in over 19 active clinical and commercial programs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.